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Background: The aim of this study was to clarify the current status in the effective control of dyslipidemia
in Taiwanese women and men with coronary heart disease (CHD).
Materials and methods: A total 1584 patients with CHD (1188 men, aged 64.8  11.6 years and 396
women, aged 69.0  9.8 years) from 3486 patients who had atherosclerotic vascular disease and com-
plete lipids measured values [total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), tri-
glycerides (TG), and low-density lipoprotein cholesterol (LDL-C)] were used for analysis.
Results: The waist, height, weight, and creatinine levels were higher in men than in women. The systolic
blood pressure, TC, HDL-C, LDL-C, fasting blood glucose, and platelet were lower in men than in women.
Men were more likely to achieve the target goal than women in TC < 160 mg/dL, LDL-C < 100 mg/dL, and
TG < 150 mg/dL as well as to achieve HDL-C goal.
Conclusion: A signiﬁcant gap was found between the guidelines and clinical practice in statin inter-
vention among these CHD patients, particularly for women. The strategy in control of dyslipidemia
should consider gender difference.
Copyright  2013, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Low-density lipoprotein cholesterol (LDL-C) reduction by statin
therapy has shown beneﬁts in decreasing morbid and mortal car-
diovascular events in both the secondary and primary prevention
trials of coronary heart disease (CHD)1e5. However, subgroup
analysis did not consistently show beneﬁts in women compared
with men in secondary prevention trials. In addition, usually the
percent of female participants ranged from 20% to 30% in statinal involvement in, within the
n or entity with a ﬁnancial
or materials discussed in the
lar Division, Department of
tion 2, Chung San North Road,
).
iwan Society of Geriatric Emergentrials. The Heart Protection Study showed further beneﬁt could be
achieved by lowering the LDL-C level to below 100 mg/dL in high-
risk patients5. In the Translating Research Into Action for Diabetes
(TRIAD) study, women were signiﬁcantly more likely than men to
have LDL-C  130 mg/dL6. Women were found to relatively receive
a less aggressive approach to cardiovascular risk factors and,
mostly, to a less intense cholesterol management than men7.
Therefore, the focus on cardiovascular risk management in women
is rising. Nevertheless, all these lipid-lowering trials (LLTs) were
mainly conducted in Europe and American and data from Asians
were fragmented.
The gender gap between guidelines and clinical practice
remained elusive in Taiwan. To clarify the issue, we explored
gender-related differences in the rates of achieving the target
LDL-C levels suggested by National Cholesterol Education Pro-
gram Adult Treatment Panel III (NCEP ATP III)8 in patients with
coronary heart disease from the Taiwanese Lipid Registry Study
(TLRS).cy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Demographic data of men and womenwith myocardial infarction or coronary artery
disease.
Men (n ¼ 1188) Women (n ¼ 396) p
Age (y) 64.8  11.6 69.0  9.8 <0.0001
Waist (cm) 95.3  9.6 90.8  10.7 <0.0001
Height (cm) 166.2  6.0 153.5  5.8 <0.0001
Weight (kg) 72.7  11.2 62.4  10.7 <0.0001
BMI (kg/m2) 26.3  3.5 26.5  4.3 0.41
SBP (mmHg) 131.3  17.6 135.9  18.9 <0.0001
TC (mg/dL) 167.8  39.2 178.9  43.5 <0.0001
HDL-C (mg/dL) 43.1  12.6 50.4  16.7 <0.0001
LDL-C (mg/dL) 97.4  33.4 101.5  36.0 0.04
TG (mg/dL) 141.0  98.3 144.1  101.4 0.59
Creatinine (mg/dL) 1.22  0.78 1.03  0.85 0.0001
FBG (mg/dL) 118.3  40.8 123.1  42.5 0.05
HbA1C, % 7.0  1.4 7.2  1.4 0.05
Current Smoking 217 (18.3) 14 (3.5) 0.006
History of HTN 827 (69.6) 327 (82.6) <0.0001
History of DM or IGT 458 (38.6) 216 (54.6) <0.0001
History of ischemic stroke 39 (3.3) 15 (3.8) 0.64
History of nonischemic stroke 22 (1.9) 12 (3.1) 0.16
History of TIA 23 (2.0) 11 (2.8) 0.32
Alcohol consumption 233 (19.6) 14 (3.5) <0.0001
Lipid-lowering agents
Statin, yes 873 (73.4) 288 (72.7) 0.09
Atorvastatin 300 (25.3) 107 (27.0) 0.49
Rosuvastatin 373 (31.4) 110 (27.78) 0.18
Simvastatin 68 (5.7) 20 (5.0) 0.61
Fluvastatin 81 (6.82) 22 (5.56) 0.38
Pravastatin 51 (4.29) 29 (7.32) 0.02
Statin, no 315 (26.5) 108 (27.3) 0.77
Statin equivalent dose 2.08  2.00 1.98  1.92 0.39
Fibrate 66 (5.56) 19 (4.80) 0.56
Ezetimibe or cholestyramine 111 (9.3) 31 (7.8) 0.36
Niacin or acipimox 2 (0.17) 1 (0.25) 0.74
Data are presented as yes (%) unless otherwise stated.
BMI ¼ body mass index; DM ¼ diabetes mellitus; FBG ¼ fasting blood glucose;
HbA1c ¼ hemoglobin A1c; HDL-C ¼ high density lipoprotein cholesterol;
HTN ¼ hypertension; IGT ¼ impaired glucose tolerance; LDL-C ¼ low density li-
poprotein cholesterol; SBP ¼ systolic blood pressure; TC ¼ total cholesterol;
TG ¼ triglyceride; TIA ¼ transient ischemic stroke.
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2.1. Study population
Taiwanese Secondary Prevention for patients with AtheRo-
sCLErotic disease (T-SPARCLE) Registry was initiated by Taiwan
society of lipids and atherosclerosis in 2011 for investigating the
control of dyslipidemia and the association between dyslipidemia
and future cardiovascular events. Twelve hospitals (8 medical
centers and 6 regional hospitals) were invited to participate in this
registry (T-SPARCLE). The enrollment criteria were as follows9: (1)
patients with atherosclerotic vascular diseases, including coronary
atherosclerosis as diagnosed by cardiac catheterization examina-
tion, history of myocardial infarction as evidenced by electrocar-
diography (ECG) or hospitalization, angina diagnosed by ischemic
ECG changes, or positive response to stress test; (2) patients with
cerebral vascular disease, cerebral infarction, and intracerebral
hemorrhage, excluding those with intracerebral hemorrhage
caused by other diseases (such as cancer); and patients with tran-
sient ischemic attack (TIA) whose carotid artery duplex showed
atheromatous change with more than 70% stenosis. Peripheral
atherosclerosis with symptoms of ischemia and conﬁrmed by
Doppler ultrasound or angiography.
There were 4361 participants meeting the enrollment criteria.
Finally, a total of 3486 patients (2386 men and 1100 women) with
complete lipids measure values [total cholesterol (TC), high-density
lipoprotein cholesterol (HDL-C), triglycerides (TG), and low-density
lipoprotein cholesterol (LDL-C)] were included in this analysis. Data
of demographic characteristics, medical history, and drug history
were collected. Hypertension (HTN) was deﬁned as: (1) known
history of hypertension; (2) taking antihypertensive drugs at
referral; and (3) systolic blood pressure (BP) 140 mmHg or dia-
stolic BP  90 mmHg by medical chart review. Those patients with
an established diagnosis of diabetes mellitus (DM) or those on
glucose lowering drugs or fasting glucose  126 mg/dL were
labeled as DM. Fasting glucose level between 100 mg/dL and
126 mg/dL was deﬁned as impaired glucose tolerance (IGT). The
1584 patients with CHD were included in our analysis. Lipid-
lowering agents were prescribed following the National Choles-
terol Education Program Adult Treatment Panel III (NCEP ATP III)
guidelines8. As the potency of statins was different10, statin
equivalent doses were calculated as given in Appendix 1. All pa-
tients had given written informed consent for this study, and this
study had been proved by Joint Institute Review Board, Taiwan.
2.2. Statistical methods
Data are expressed as mean  SD or percentage. Student t test
was applied to the continuous data, and Chi-square tests of cate-
gorical data were used to compare the differences between groups.
Multivariate logistic regression analysis were used to examine the
odds of optimal lipid value attainment [TC < 160 mg/dL,
TG < 150 mg/dL, LDL-C < 100 mg/dL, and HDL-C (men: 40 mg/dL
and women: 50 mg/dL)]. Age, gender, body mass index (BMI),
history of HTN, history of DM or IGT, smoking status, and status of
alcohol consumption were included in the model to assess their
impact on goal attainment. The participants without optimal lipid
value attainment were considered as the reference group. All an-
alyses were performed with SAS statistical software version 9.2
(SAS Institute, Carey, NC, USA).
3. Results
The demographic data of 1188 men (aged 64.8  11.6 years) and
396 women (69.0  9.8 years) are shown in Table 1. Most of theparticipants were men (75%). More than 90% of women were older
than 55 years. Men were signiﬁcantly younger and had higher
waist, height, weight, and creatinine levels than women. The BMI
and TG levels were not different between men and women. Men
had signiﬁcantly lower systolic blood pressure (SBP), TC, HDL-C,
LDL-C, and fasting blood glucose than women. The percentages of
history of HTN, diabetes, or IGT were lower in men than in women.
Men were much more likely to smoke and drink alcohol than
women. The percentages of statin use in men and women were
68.5% and 65.4%, respectively. Women were signiﬁcantly more
likely to take pravastatin than men. The percentage of ﬁbrate use in
men and women was not different (p ¼ 0.56).
The men taking statin were more likely than women to achieve
the goal of TC (<160 mg/dL), HDL-C (40 mg/dL in men compared
to 50 mg/dL in women) and LDL-C (<100 mg/dL) (Table 2). Such
trends did not exist with other lipid-lowering agents.
To further clarify the factors associated with effective control of
dyslipidemia, the logistic regression model was performed
(Table 3). Men were more likely to achieve the target goal than
women in TC < 160 mg/dL [adjusted odds ratio (OR): 2.31,
p < 0.0001], in HDL-C ( 40 mg/dL in men compared to50 mg/dL
in women; adjusted OR:1.64, p ¼ 0.0002), in LDL-C < 100 mg/dL
(adjusted OR: 1.41, p ¼ 0.009) and in TG < 150 mg/dL (adjusted OR:
1.38, p ¼ 0.03). Regarding age, increased age had odds to have
optimal lipid control. As men had a higher percentage of attaining
the goal than women, we separately investigated the determinants
of goal attainment betweenmen and women. Patients taking statin
led to a statistically signiﬁcant beneﬁt in attaining TC < 160 mg/dL
Table 2
The percentage of goal attainment in patients taking lipid-lowering agents.
TC < 160 mg/dL HDL-C  40/50 mg/dLa LDL-C < 100 mg/dL TG < 150 mg/dL
Men Women p Men Women p Men Women p Men Women p
Statin (men ¼ 873; women ¼ 288) 446 (51.1) 99 (34.4) <0.0001 497 (56.9) 133 (46.2) 0.002 549 (62.9) 161 (55.9) 0.04 605 (69.3) 192 (66.7) 0.40
Fibrate (men ¼ 66; women ¼ 19) 20 (30.3) 8 (42.1) 0.33 21 (31.8) 3 (15.8) 0.17 38 (57.6) 10 (52.6) 0.70 16 (24.2) 5 (26.3) 0.85
Ezetimibe and cholestyramine
(men ¼ 76; women ¼ 19)
29 (38.2) 6 (31.6) 0.58 46 (60.5) 12 (63.2) 0.83 40 (52.6) 7 (36.8) 0.22 45 (59.2) 14 (73.7) 0.24
Niacin and acipimox
(men ¼ 2;women ¼ 1)
0 0 e 1 (50) 0 0.39 2 (100) 1 (100) 0 0
Data are presented as (%).
HDL-C ¼ high density lipoprotein cholesterol; LDL-C ¼ low density lipoprotein cholesterol; TC ¼ total cholesterol; TG ¼ triglyceride.
a HDL-C: in men 40 mg/dL; in women 50 mg/dL.
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1.44, p ¼ 0.002) and TG < 150 mg/dL (adjusted OR:1.42, p¼ 0.005),
compared to those not taking statin. For men, those taking statin
were more likely to achieve TC < 160 mg/dL (adjusted OR: 1.89,
p < 0.0001), LDL-C <100 mg/dL (adjusted OR: 1.52, p ¼ 0.002), and
TG < 150 mg/dL (adjusted OR: 1.60, p ¼ 0.002), but no similar
trends were found in women. The effect of statin on achieving the
TC, LDL-C, and TG goals was also statistically signiﬁcant in patients
with DM or IGT.
By contrast, an increased BMI was associated with a decrease in
OR of TG and HDL (HDL > 40 mg/dL in men and HDL > 50 mg/dL in
women) goal attainment. An increased age led to an increase in OR
of attaining TC, LDL-C, HDL-C, and TG goals. Participants who were
current smokers and with DM or IGT had decreased ORs of TG goal
attainment. As the potencies of statins were different, we use statin
equivalent doses instead of statin use (yes vs. no) in logistic
regression models (Table 4). Compared to women, men were more
likely to achieve the target goal than women in TC < 160 mg/dL
(adjusted OR: 2.27, p < 0.0001), in HDL-C ( 40 mg/dL in men or
50 mg/dL in women; adjusted OR: 1.64, p ¼ 0.0002), in LDL-
C < 100 mg/dL (adjusted OR: 1.40, p ¼ 0.01) and in TG < 150 mg/dL
(adjusted OR: 1.38, p ¼ 0.03). As a whole, patients taking statin had
a statistically signiﬁcant beneﬁt in attaining TC < 160 mg/dL
(adjusted OR: 1.54, p ¼ 0.0001), LDL-C < 100 mg/dL (adjusted OR:
1.37, p ¼ 0.005) and TG < 150 mg/dL (adjusted OR: 1.45, p ¼ 0.002).
For men, those taking statin were more likely to achieve TC
(adjusted OR: 1.75, p < 0.0001), HDL-C ( 40 mg/dL in men or
50 mg/dL in women; adjusted OR: 1.33, p ¼ 0.04), LDL-
C < 100 mg/dL (adjusted OR: 1.46, p ¼ 0.004), and TG goals
(adjusted OR: 1.69, p ¼ 0.002), but no similar trends were found in
women. The effects of statin on achieving the TC, HDL-C, and LDL-C
goals were statistically signiﬁcant in patients with DM or IGT. An
increased BMI was associated with a decrease in ORs of TG and HDL
(HDL > 40 mg/dL in men and HDL > 50 mg/dL in women) goal
attainments. Patients who were current smokers and with DM or
IGT had decreased ORs of TG goal attainments.
4. Discussion
The results of the present study indicated a signiﬁcant gender
disparity in attaining the TC, LDL-C, HDL-C, and TG goals in
Taiwanese patients with CHD. In the Heart and Estrogen/Progestin
Replacement Study (HERS), only a small proportion of women
(9.5%) reached the LDL-C levels below 100 mg/dL11. The south-
eastern US health plan indicated that only 17% of women had an
LDL-C < 100 mg/dL, and 7% attained an LDL-C < 100 mg/dL, HDL-C
> 50 mg/dL, and TG > 150 mg/dL12. The results of the European
Action on Secondary Prevention through Intervention to Reduce
Event (EUROASPIRE) III showed that despite similarities in medi-
cation exposure, women are less likely than men to achieve LDL-C
target goal (LDL-C < 2.5 mmol/L, 97 mg/dL) after a coronaryevent13. The Lipid Treatment Assessment Project (L-TAP) 2 indi-
cated that in 9955 of patients (45.3% women) evaluated, women
had a signiﬁcantly lower overall LDL-C success rate than men7.
Similar results have been demonstrated in China14,15. The ﬁndings
of the present study are consistent with those of all the above
mentioned studies.
In our study, men taking statin were more likely to achieve the
LDL-C goal than women taking statin, despite the exposures of
statin equivalent dose betweenmen andwomen being comparable.
This result might be partially explained by the effect of estrogen on
lipid metabolism. In our study, the average age of women was 69
years, and approximately 91.9% of women were postmenopausal.
Higher endogenous estrogen levels were reported to be associated
with increased LDL receptors and reduced activity of 3-hydroxy 3-
methylglutaryl coenzyme A reductase (HMG-CoAR)16,17. When the
estrogen levels in postmenopausal women reduced, the effect of
statins was attenuated in reducing the LDL-C level via the mecha-
nisms involving LDL receptors and metabolism. In this sense, we
should pay more attention to women with CHD, particularly post-
menopausal women, and give more aggressive LDL-C-lowering
treatment than men.
In the Maryland-based health maintenance organization study,
there was no difference between the proportion of men (71.4%) and
women (63.3%) prescribed lipid-lowering therapy. As a result, more
men (51.0%) than women (36.7%) reached the LDL-C of
<2.59 mmol/L (<100 mg/dL)18. A report from China showed that in
patients with high cardiovascular risk, the rate of statin therapy
was much higher (82.2%); however, the LDL-C attainment
(<2.6 mmol/L, 100 mg/dL) rate was relatively lower in men (45.5%)
and women (28.5%)15. In our study, statin was prescribed to men
(73.4%) and women (72.7%), but the LDL-C target attainment rate
was 51.1% for men and 34.4% for women. Together, these data
indicated that the gap between the rate of goal attainment and
statin therapy was still widening, particularly in women.
Higher goal attainment rates could be achieved with higher
doses of statin19. In the present study, moderate doses of statin
were given. Even though men took statin doses comparable with
women, the men taking statin were more likely to attain the lipid
goal than thewomen in the present study. It has been shown that in
patients with CHD and risk equivalents, fewer women than men
achieved the lipid goal partly owing to the inadequate dose of
statin20. This might be due to the incorrect perception of both
women and their physicians regarding the cardiovascular risk in
women. A previous study showed that physicians perceived
women to be at a lower risk than men, even if they had a similar
calculated CHD risk21, and this led to the undertreatment of women
with dyslipidemia. However, in Taiwan, the undertreatment of
dyslipidemia is not seen for women alone. A previous Taiwanese
study conducted in a medical center showed that only 31% of pa-
tients with cardiovascular disease reached the LDL-C target22.
Although medical expenses in Taiwan are mainly covered by the
Table 3
Contributions of statin use and other covariates in gender difference in optimal lipid goal attainment among patients with coronary artery disease.
Achieving TC < 160 mg/dL
All (n ¼ 1584) p Men p Women p
(n ¼ 1188) (n ¼ 396)
AOR (95% CI) AOR (95% CI) AOR (95% CI)
Age (y) 1.02 (1.01,1.03)* 0.003 1.02 (1.01,1.03)* 0.002 1.01 (0.99,1.03) 0.46
BMI (kg/m2) 0.99 (0.96,1.02) 0.40 0.99 (0.96,1.03) 0.66 0.98 (0.93,1.03) 0.40
Smoking status 0.94 (0.74,1.18) 0.58 0.93 (0.73,1.18) 0.53 0.93 (0.36,2.40) 0.88
History of DM or IGT 1.47 (1.19,1.81)* 0.0003 1.50 (1.18,1.90)* 0.001 1.36 (0.88,2.12) 0.17
History of HTN 1.08 (0.85,1.36) 0.55 1.09 (0.84,1.42) 0.51 0.99 (0.56,1.77) 0.98
Alcohol consumption 0.84 (0.63,1.12) 0.23 0.90 (0.67,1.22) 0.51 0.15 (0.02,1.16) 0.07
Statin 1.75 (1.38,2.23)* <0.0001 1.89 (1.44,2.49)* <0.0001 1.46 (0.89,2.39) 0.13
Gender 2.31 (1.76,3.03)* <0.0001
Achieving HDL > 40 mg/dL in men and HDL > 50 mg/dL in women
All (n ¼ 1584) p Men p Women p
(n ¼ 1188) (n ¼ 396)
AOR (95% CI) AOR (95% CI) AOR (95% CI)
Age (y) 1.02 (1.01,1.03)* <0.0001 1.02 (1.01,1.03)* <0.0001 1.01 (0.99,1.03) 0.40
BMI (kg/m2) 0.95 (0.93,0.98)* 0.001 0.93 (0.90,0.96)* <0.0001 1.00 (0.95,1.05) 0.98
Smoking status 0.82 (0.65,1.03) 0.09 0.83 (0.65,1.06) 0.13 0.94 (0.38,2.31) 0.89
History of DM or IGT 0.70 (0.57,0.86)* 0.0008 0.80 (0.63,1.02) 0.07 0.48 (0.32,0.72)* 0.0004
History of HTN 1.03 (0.82,1.31) 0.79 1.02 (0.78,1.33) 0.88 1.16 (0.67,2.00) 0.60
Alcohol consumption 1.13 (0.84,1.51) 0.42 1.17 (0.87,1.59) 0.30 1.03 (0.35,3.09) 0.95
Statin 1.17 (0.93,1.48) 0.18 1.27 (0.97,1.68) 0.09 0.93 (0.59,1.47) 0.77
Gender 1.64 (1.26,2.13)* 0.0002
Achieving LDL-C < 100 mg/dL
All (n ¼ 1584) p Men p Women p
(n ¼ 1188) (n ¼ 396)
AOR (95% CI) AOR (95% CI) AOR (95% CI)
Age (y) 1.02 (1.01,1.03)* 0.002 1.01 (1.00,1.03)* 0.01 1.03 (1.01,1.05)* 0.02
BMI (kg/m2) 0.98 (0.96,1.01) 0.22 0.98 (0.95,1.02) 0.28 0.99 (0.94,1.03) 0.53
Smoking status 0.99 (0.79,1.25) 0.95 0.94 (0.74,1.20) 0.62 1.62 (0.63,4.15) 0.31
History of DM or IGT 1.27 (1.03,1.57)* 0.03 1.23 (0.96,1.57) 0.10 1.34 (0.89,2.04) 0.17
History of HTN 0.94 (0.74,1.19) 0.58 0.98 (0.75,1.28) 0.89 0.77 (0.44,1.34) 0.35
Alcohol consumption 0.99 (0.74,1.32) 0.95 1.10 (0.81,1.49) 0.54 0.21 (0.06,0.78)* 0.02
Statin 1.44 (1.14,1.81)* 0.002 1.52 (1.16,1.99)* 0.002 1.28 (0.81,2.01) 0.30
Gender 1.41 (1.09,1.84)* 0.009
Achieving TG < 150 mg/dL
All (n ¼ 1584) p Men p Women p
(n ¼ 1188) (n ¼ 396)
AOR (95% CI) AOR (95% CI) AOR (95% CI)
Age (y) 1.03 (1.02,1.04)* <0.0001 1.04 (1.02,1.05)* <0.0001 1.01 (0.99,1.03) 0.43
BMI (kg/m2) 0.93 (0.90,0.96)* <0.0001 0.91 (0.87,0.94)* <0.0001 0.98 (0.93,1.02) 0.31
Smoking status 0.69 (0.54,0.89)* 0.004 0.70 (0.54,0.91)* 0.008 0.76 (0.31,1.88) 0.56
History of DM or IGT 0.80 (0.64,1.00)* 0.04 0.79 (0.61,1.03) 0.08 0.81 (0.52,1.24) 0.33
History of HTN 0.93 (0.72,1.20) 0.57 0.97 (0.73,1.30) 0.85 0.81 (0.45,1.45) 0.48
Alcohol consumption 0.93 (0.69,1.27) 0.66 0.95 (0.69,1.30) 0.74 1.20 (0.37,3.98) 0.76
Statin 1.42 (1.11,1.82)* 0.005 1.60 (1.19,2.14)* 0.002 1.08 (0.68,1.74) 0.74
Gender 1.38 (1.04,1.84)* 0.03
Data (smoking status, history of DM or IGT, history of HTN, alcohol consumption, statin) are presented as (yes vs. no).
*:p < 0.05.
AOR ¼ adjusted odds ratio; BMI ¼ body mass index; DM ¼ diabetes mellitus; HDL-C ¼ high density lipoprotein cholesterol; HTN ¼ hypertension; IGT ¼ impaired glucose
tolerance; LDL-C ¼ low density lipoprotein cholesterol; TC ¼ total cholesterol; TG ¼ triglyceride.
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and the statement of NHI payment for drugs used for dyslipidemia
may inﬂuence the physician’s behavior. One such example is the
global budget system of NHI, inwhich physicians may choose not to
titrate statin aggressively to a high dose. Another point of consid-
eration is whether physicians are hesitant to prescribe statin or give
more intensive statin therapy because of the concern about statin
safety. A recent guideline from the American Heart Association
recommended statin therapy to achieve the same LDL-C goals in
women as in men23. Improving awareness of achieving lipid goal inwomen among physicians is an important step to rectify the
undertreatment in women.
According to lipid treatment guidelines, the patients with
chronic diseases such as HTN and DM have more strict lipid-
lowering treatment goals. The present study also showed that
cardiovascular comorbidities and risk factors were associated with
reaching lipid-lowering treatment goals. However, even the prev-
alence rate of HTN and DM or IGT was higher in women and men
with DM or IGT were more likely to attain the TC goal thanwomen.
We also found that menwith higher BMI are difﬁcult to achieve the
Table 4
Contributions of statin equivalent dose and other covariates in gender difference in optimal lipid goal attainment among patients with coronary artery disease.
Achieving TC < 160 mg/dL
All (n ¼ 1584) p Men p Women p
(n ¼ 1188) (n ¼ 396)
AOR (95% CI) AOR (95% CI) AOR (95% CI)
Age (y) 1.01 (1.01,1.02)* 0.004 1.02 (1.01,103)* 0.003 1.01 (0.99,1.03) 0.45
BMI (kg/m2) 0.99 (0.96,1.02) 0.34 0.99 (0.96,1.03) 0.61 0.98 (0.93,1.03) 0.42
Smoking status 0.94 (0.75,1.19) 0.60 0.92 (0.73,1.17) 0.51 0.97 (0.38,2.49) 0.95
History of DM or IGT 1.47 (1.19,1.81)* 0.0004 1.49 (1.17,1.90)* 0.001 1.35 (0.87,2.10) 0.18
History of HTN 1.06 (0.84,1.35) 0.61 1.08 (0.84,1.41) 0.54 0.98 (0.55,1.75) 0.95
Alcohol consumption 0.83 (0.62,1.11) 0.20 0.89 (0.66,1.21) 0.47 0.16 (0.02,1.21) 0.08
Statin equivalent dose 1.54 (1.24,1.93)* 0.0001 1.75 (1.35,2.27)* <0.0001 1.12 (0.71,1.75) 0.63
Gender 2.27 (1.73,2.97)* <0.0001
Achieving HDL > 40 mg/dL in men and HDL > 50 mg/Dl in women
All (n ¼ 1584) p Men p Women p
(n ¼ 1188) (n ¼ 396)
AOR (95% CI) AOR (95% CI) AOR (95% CI)
Age (y) 1.02 (1.01,1.03)* <0.0001 1.02 (1.01,1.03)* <0.0001 1.01 (0.99,1.03) 0.39
BMI (kg/m2) 0.95 (0.93,0.98)* 0.0009 0.93 (0.90,0.96)* <0.0001 1.00 (0.95,1.05) 0.98
Smoking status 0.82 (0.65,1.03) 0.09 0.82 (0.64,1.05) 0.11 0.94 (0.38,2.32) 0.90
History of DM or IGT 0.70 (0.57,0.86)* 0.0008 0.80 (0.63,1.02) 0.07 0.48 (0.31,0.72)* 0.0004
History of HTN 1.03 (0.82,1.31) 0.78 1.03 (0.79,1.33) 0.86 1.15 (0.67,1.99) 0.61
Alcohol consumption 1.12 (0.84,1.50) 0.43 1.17 (0.86,1.58) 0.31 1.06 (0.35,3.17) 0.92
Statin equivalent dose 1.19 (1.96,1.49) 0.12 1.33 (1.02,1.72)* 0.03 0.87 (0.57,1.34) 0.53
Gender 1.64 (1.26,2.12)* 0.0002
Achieving LDL-C < 100 mg/dL
All (n ¼ 1584) p Men p Women p
(n ¼ 1188) (n ¼ 396)
AOR (95% CI) AOR (95% CI) AOR (95% CI)
Age (y) 1.02 (1.01,1.03)* 0.002 1.01 (1.00,1.03)* 0.02 1.03 (1.01,1.05)* 0.02
BMI(kg/m2) 0.98 (0.95,1.01) 0.19 0.98 (0.95,1.02) 0.26 0.98 (0.94,1.03) 0.51
Smoking status 0.99 (0.79,1.25) 0.95 0.94 (0.74,1.20) 0.60 1.64 (0.64,4.19) 0.30
History of DM or IGT 1.27 (1.03,1.57)* 0.03 1.23 (0.96,1.57) 0.10 1.34 (0.88,2.03) 0.17
History of HTN 0.93 (0.74,1.18) 0.56 0.98 (0.75,1.27) 0.86 0.77 (0.44,1.34) 0.35
Alcohol consumption 0.99 (0.74,1.32) 0.92 1.09 (0.81,1.48) 0.57 0.21 (0.06,0.79)* 0.02
Statin equivalent dose 1.37 (1.10,1.70)* 0.005 1.46 (1.13,1.89)* 0.004 1.20 (0.78,1.84) 0.41
Gender 1.40 (1.08,1.82)* 0.01
Achieving TG < 150 mg/dL
All (n ¼ 1584) p Men p Women p
(n ¼ 1188) (n ¼ 396)
AOR (95% CI) AOR (95% CI) AOR (95% CI)
Age (y) 1.03 (1.02,1.04)* <0.0001 1.04 (1.02,1.05)* <0.0001 1.01 (0.99,1.03) 0.43
BMI (kg/m2) 0.93 (0.90,0.96)* <0.0001 0.91 (0.87,0.94)* <0.0001 0.98 (0.93,1.03) 0.33
Smoking status 0.69 (0.54,0.89)* 0.004 0.69 (0.53,0.90)* 0.006 0.78 (0.32,1.90) 0.58
History of DM or IGT 0.80 (0.64,0.99)* 0.04 0.79 (0.61,1.03) 0.08 0.81 (0.52,1.24) 0.33
History of HTN 0.93 (0.72,1.21) 0.60 0.98 (0.735,1.31) 0.89 0.81 (0.45,1.45) 0.47
Alcohol consumption 0.93 (0.68,1.26) 0.63 0.94 (0.68,1.30) 0.71 1.23 (0.37,4.06) 0.74
Statin equivalent dose 1.45 (1.15,1.83)* 0.002 1.69 (1.28,2.24)* 0.0002 0.99 (0.63,1.54) 0.95
Gender 1.38 (1.04,1.83)* 0.03
Data (smoking status, history of DM or IGT, history of HTN, alcohol consumption) are presented as (yes vs. no).
*:p < 0.05.
AOR ¼ adjusted odds ratio; BMI ¼ body mass index; DM ¼ diabetes mellitus; HDL-C ¼ high density lipoprotein cholesterol; HTN ¼ hypertension; IGT ¼ impaired glucose
tolerance; LDL-C ¼ low density lipoprotein cholesterol; TC ¼ total cholesterol; TG ¼ triglyceride.
C.-Y. Chen et al.120HDL-C goal. Reaching these lipid-lowering goals will be a greater
challenge for the high-risk patients, especially for the women, who
were more likely to have comorbidities as shown in the present
study. This may contribute to the gender disparity in the lipid-
lowering goal.
There are several limitations in the present study. First, our
study was a cross-sectional study and the results may not reﬂect
beyond the study population. However, our study provided the
benchmark data of lipid goal attainment rate. Second, indeed, the
registry data we use, although it provided comprehensive data onmany variables, it should be mentioned that there may be some
factors such as patient’s preferences, attitudes, physical activity,
dietary habits, adherence to lipid-lowering agents, education
levels, and using oral contraceptives inﬂuencing goal attainment.
The poorer socioeconomic factor had been reported to affect goal
attainment14. However, health insurance in Taiwan covered by NHI
may attenuate the effect of socioeconomic factors. These unob-
served characteristics and behaviors may be potential sources of
residual confounding. Further research is needed to these potential
effects. Third, the number of women enrolled in our study was less
Gender Difference in Control of Dyslipidemia 121than the number of men, and the women were older than men.
Selection bias may lead to difference in gender-related goal
attainment because women enrolled in our study may have more
severe dyslipidemia than men. In addition, it is difﬁcult to estimate
the extent of selection bias effect on gender disparity in achieving
goal attainment rates. A follow-up study that focuses on these
points needs to be conducted.
Our results have signiﬁcant implications for clinical practice.
Most of the factors in our study are modiﬁable. Physicians should
attempt to narrow the gender-related lipid-lowering treatment gap
by paying more attention to women, especially postmenopausal
women and those with high LDL-C levels, providing an optimal
treatment strategy to women.Appendix 1
The calculation of statin equivalent doses according to dose efﬁcacy of statin-based
therapies for LDL-C reduction.
Equi-
valent
dose of
statin
Lovastatin Pravastatin Simvastatin Fluvastatin Atorvstatin Rosuvastatin
1 dose 20 20 10 40 5 2.5
2 dose 40 40 20 80 10 5
4 dose 80 80 40 20 10
8 dose 80 40 20
Data are presented as mg.10References
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